Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

NCT02362035 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02362035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02362035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies
Lead sponsor
Acerta Pharma BV
Phase
Phase 1/2
Overall status
Completed
Start date
February 20, 2015
Completion date
October 27, 2025
Enrollment
161 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, cll, follicular lymphoma (fl), hairy cell leukemia, hodgkin lymphoma, indolent non hodgkin lymphoma, mantle cell lymphoma (mcl), marginal zone lymphomas, mediastinal large b cell lymphoma, multiple myeloma, richter's syndrome, small lymphocytic lymphoma (sll), waldenström macroglobulinemia